Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027638 · ClinicalTrials.gov registry record · Phase 2
Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00027638: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00027638 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00027638, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Thalidomide may stop the growth of neuroendocrine tumors by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have metastatic neuroendocrine tumors.
Interventions
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-03 |
| Est. Completion | 2003-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00027638
The ClinicalTrials.gov registry entry for NCT00027638 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which thalidomide is the first listed.
NCT00027638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00027638 about?
NCT00027638 is a clinical study titled "Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors". RATIONALE: Thalidomide may stop the growth of neuroendocrine tumors by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have metastatic neuroendocrine tumors.
What is the current status of trial NCT00027638?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-03. Estimated completion is 2003-12.
What interventions are being tested in trial NCT00027638?
The interventions under investigation include: thalidomide (DRUG).
Who is sponsoring clinical trial NCT00027638?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.